A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

Summary

The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.

Timeline

Start

2025-01-30

Primary completion

2028-01-31

Completion

2030-01-31

Drugs

Indications